Maurer M, Berger W, Gimenez-Arnau A, Hayama K, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol 2022;150:1498-1506.
PMID: 36096203